Supplementary Table S1: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan Akaike information criterion test (AIC <
(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).
